Top Digital Health Investors to Know in 2026

Digital health funding cooled significantly from the 2021 peak, but it has not dried up. Active investors have grown more selective, which means the bar for getting a meeting is higher, but the firms that are writing checks are writing meaningful ones. Knowing who they are and what they actually invest in is the starting point for any HealthTech founder building a target list.

According to the Rock Health 2025 year-end funding report, digital health funding in the US stabilised in the $10-12B range annually after the correction from 2021's record $29B. The deals being written are concentrated in AI-enabled diagnostics, care navigation, and employer-facing wellness platforms.

Here are 12 active investors writing checks in HealthTech and digital health in 2026.

The Investors

How to Read This List

Not all 12 firms are right for every HealthTech company. A few distinctions that matter when you are building your target list:

Rock Health, Define Ventures, and Flare Capital Partners are the most consistently active at seed and early Series A for pure digital health and health tech companies. They have dedicated funds for this space, and their partners spend most of their time in the sector.

General Catalyst and a16z Bio + Health write larger checks and tend to come in at Series A and beyond when there is measurable traction. Getting in front of them at pre-seed or early seed usually means a "come back when you have more data" response.

Optum Ventures and Kaiser Permanente Ventures (not listed above but worth tracking) are strategic corporate VCs tied to large health systems. They bring distribution relationships and clinical network access alongside capital, but their investment process is slower and their strategic interests shape what they fund.

GV invests across sectors but has a consistently active health portfolio. They typically invest at Series A and beyond and bring Google's platform and data relationships as potential value-add.

What HealthTech Investors Check in Your Data Room

Digital health fundraising requires documents that general tech investors don't ask for. Before you share your data room with any of these firms, make sure you have:

• Regulatory status: Are you a medical device (FDA), a wellness product, or something in between? Investors need to understand your regulatory pathway or lack thereof.
• Clinical evidence: Peer-reviewed studies, white papers, or pilot data. The strength of your clinical evidence is often the key differentiator at the Series A stage.
• Reimbursement model: How does the product get paid for? Insurance, employer, out-of-pocket, or government? This shapes your go-to-market and revenue trajectory more than almost anything else.
• HIPAA compliance documentation: Investors will ask. Have your BAAs, data handling policy, and security documentation ready.
• Pilot agreements or LOIs: Health system partnerships take time, but investors want to see evidence of clinical validation. Even a two-site pilot with preliminary data matters.

Pitchwise lets you track exactly which documents your health investors open and how long they spend on each. Clinical evidence and regulatory documentation tend to get disproportionate attention compared to other data rooms because these are the differentiated risk factors for health investments.

How to Approach These Investors

Warm introductions from portfolio founders remain the highest-conversion path. Most of these firms publish their portfolio on their websites. Identify founders in their portfolio building in adjacent spaces and ask for introductions through your network. 

Conferences also matter more in HealthTech than in general tech. HLTH, JP Morgan Healthcare Conference, and ViVE are where digital health VCs actually show up. An in-person conversation at a relevant conference is worth more than a cold email.

Be specific about your category when you reach out. "Digital health" is too broad. "AI-enabled prior authorisation for speciality pharma" is specific. The more precisely you can describe your category and why it matters now, the easier it is for an investor to know whether you fit their thesis without a meeting.

FAQ: HealthTech Investors

Do I need clinical traction to raise from these investors at seed?

At seed, most digital health investors will fund pre-clinical traction if the regulatory pathway is clear, the team has domain expertise, and the market opportunity is large. By Series A, some form of clinical validation or pilot data is typically required. Define Ventures and Flare Capital specifically fund at the hypothesis stage.

Should I approach strategic investors like Optum Ventures alongside traditional VCs?

Yes, but understand the tradeoff. A strategic investor can create distribution advantages and credibility with health systems. They can also complicate future fundraising if competitors perceive you as too closely tied to a single health system. Many founders take strategic investment in the form of a smaller check alongside a lead institutional VC to mitigate this perception.

How do I know if a digital health fund is still actively investing?

Check their public portfolio page for recent investments. If the most recent portfolio company listed is from 2023, the fund may be in harvest mode rather than deploying new capital. Crunchbase and PitchBook track investment dates if the firm doesn't publish them. It is also worth checking whether the managing partners are still listed and whether they have been speaking at recent conferences.

How should I track investor engagement once I've shared materials?

Most founders send a deck and then wait, with no signal as to whether anyone read it. Pitchwise solves this: when you share your deck or data room through Pitchwise, you get real-time notifications when a health investor opens your materials, which slides or documents they spend time on, and whether they return for a second look. For HealthTech fundraises where clinical evidence and regulatory documents are the key differentiators, knowing whether an investor spent ten minutes on your FDA pathway doc or skipped it entirely changes how you prepare for the follow-up conversation.